Glucocorticoid-Induced Osteoporosis: Summary of a Workshop
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Bone remodeling is regulated by systemic and local factors, and glucocorticoids are hormones with a significant impact on the skeleton. Bone remodeling is tightly regulated, and bone formation occurs in areas of previously resorbed bone. Bone is continuously regenerated, a process that is carried out by basic multicellular units. These units are comprised by teams of juxtaposed osteoclasts and osteoblasts. These bone-resorbing and -forming cells maintain bone remodeling in an orderly fashion, and osteoclastogenesis is dependent on the genesis and presence of osteoblasts. The number of bone-forming and bone-resorbing cells present in the basic multicellular units is also dependent on an orderly cellular death or apoptosis. Therefore, cell genesis and death are critical for the maintenance of bone homeostasis. The genesis of osteoblasts and osteoclasts is governed by specific genes, local regulatory factors, and various systemic hormones, including glucocorticoids (1). Glucocorticoids decrease gastrointestinal calcium absorption, which may result in modest elevations in serum levels of PTH. However, these do not reach the hormonal levels observed in hyperparathyroidism, and the skeletal changes of glucocorticoid-induced osteoporosis (GIO) cannot be explained by excess PTH. In contrast to the changes observed in postmenopausal osteoporosis and hyperparathyroidism, where increased bone resorption prevails, bone histomorphometric analysis of patients exposed to glucocorticoids reveals only modest increases in bone resorption. Biopsies from patients with GIO display a marked depression of osteoblastic function and mineral apposition rates, whereas in postmenopausal osteoporosis and hyperparathyroidism there is no decrease in bone formation (2, 3). It is possible that the modest changes in osteoclastic resorption found in GIO are transient. Chronic treatment with glucocorticoids causes a redistribution of spontaneous PTH secretion, reducing the tonic and increasing the pulsatile release of PTH (4). This altered PTH secretion could play a secondary role in the pathophysiology of GIO. It is now apparent that most of the skeletal changes in GIO are due to direct actions of glucocorticoids in skeletal cells. Glucocorticoids regulate gene expression by transcriptional and posttranscriptional mechanisms. The transcriptional effects have been studied in greater detail, are mediated by the GR, and occur by activation or repression of gene expression (5). Activation requires the DNA binding of a receptor dimer to cognate elements in the promoter of target genes, whereas repression is mediated predominantly by protein/protein interactions between the receptor monomer and transcription factors. To discriminate the different modes of glucocorticoid action in development and physiology, mice carrying a DNA binding defective glucocorticoid receptor have been created (6, 7). In contrast to mutants with a disrupted GR gene, mice carrying a DNA binding defective glucocorticoid receptor are viable after birth, but trans-activation functions of the GR are absent. The model allows discrimination between DNA binding-dependent and -independent functions of the GR, responsible for a specific activity (6, 7). Another useful model is based on the use of targeted gene inactivation, which allows for the tissue-specific excision of a selected gene (8). Bacteriophage P1 Cre recombinase is a 38-kDa protein that recognizes the 34-bp DNA sequence loxP (locus of cross-over P1), and when loxP sites flank a gene region, Cre induces an intramolecular recombination and excision of the intervening DNA (9). This results in deletion of the DNA sequence flanked by loxP. By placing the Cre recombinase under the control of a tissue-specific promoter, the function of a gene can be examined specifically in that tissue and can be inactivated at an opportune time. For this purpose, transgenic mice overexpressing the Cre recombinase, under the control of a tissue-specific promoter, are mated with mice in which a specific gene is flanked by loxP sequences. The progeny will carry the tissue-specific gene deletion. Using this model, the GR gene has been inactivated selectively in liver, thymus, monocytes/macrophages, and brain, respectively, but targeted inactivation in skeletal tissue has not been carried out (10). This will be required to define the physiological role of glucocorticoids in bone. Levels of expression of the GR may modulate glucocorticoid action in bone, and selected cytokines, such as IL-6 and IL-11, respectively, increase and decrease GR levels, possibly sensitizing or desensitizing osteoblastic cells to the effects of glucocorticoids (11). Although the fundamental action of glucocorticoids in bone occurs by decreasing bone formation, in vivo findings in animals and humans are consistent with an early increase in bone resorption after exposure to glucocorticoids. This is probably responsible for the rapid bone loss observed in humans after the i
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Gene regulation by steroid hormones
Beato, M. (1989) · Cell · doi:10.1016/0092-8674(89)90237-7 · Cited by 3,383
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · cited 1×
“It is likely that T cell-derived cytokines, particularly RANK-L, play a role in the bone loss of experimental arthritis and human rheumatoid arthritis (37, 38).”
BackgroundKong, Y.-Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., et al. (1999) · Nature · doi:10.1038/46303 · Cited by 1,856
Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753
Use of oral corticosteroids and risk of fractures
Van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.993 · Cited by 1,263
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258 · cited 1×
“Alendronate increased BMD and decreased the incidence of vertebral fractures after 2 yr (46).”
BackgroundGiustina, A., & Veldhuis, J. D. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.6.0353 · Cited by 1,253
Self-citationDNA binding of the glucocorticoid receptor is not essential for survival
Reichardt, H. M., Kaestner, K. H., Tuckermann, J., Kretz, O., Wessely, O., Bock, R., Gass, P., Schmid, W., Herrlich, P., Angel, P., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81183-6 · Cited by 1,068 · cited 2×
“The model allows discrimination between DNA binding-dependent and -independent functions of the GR, responsible for a specific activity (6, 7).”
BackgroundHofbauer, L. C., Gori, F., Riggs, B. L., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., & Khosla, S. (1999) · Endocrinology · doi:10.1210/endo.140.10.7034 · Cited by 794 · cited 1×
“Glucocorticoids enhance RANK-L and colony-stimulating factor-1 expression and inhibit OPG production with a consequent induction of osteoclastogenesis (13, 14).”
Background
Cited by
Diagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362
“Glucocorticoids influence bone and calcium metabolism at many levels, although the exact mechanisms are not fully understood (53).”
BackgroundSelf-citationModeling the interactions between osteoblast and osteoclast activities in bone remodeling
Lemaire, V., Tobin, F. L., Greller, L. D., Cho, C. R., & Suva, L. J. (2004) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2004.03.023 · Cited by 452
Glucocorticoid-induced osteoporosis: an update
Mazziotti, G., Angeli, A., Bilezikian, J. P., Canalis, E., & Giustina, A. (2006) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2006.03.009 · Cited by 362
Self-citationSecondary Causes of Osteoporosis
FITZPATRICK, L. A. (2002) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)62214-3 · Cited by 311
RANKL Expression Is Related to the Differentiation State of Human Osteoblasts
Atkins, G. J., Kostakis, P., Pan, B., Farrugia, A., Gronthos, S., Evdokiou, A., Harrison, K., Findlay, D. M., & Zannettino, A. C. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.6.1088 · Cited by 245
“These effects of dexamethasone could lead to a net decrease in bone formation over time, consistent with its observed effects in glucocorticoid-induced osteoporosis.((48)) Clearly, the complex interplay of osteotropic factors in determining an os1096 ATKINS ET AL.”
Result
Metadata
- Authors
- Canalis, E., & Giustina, A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2001-12
- Volume
- 86
- Issue
- 12
- Pages
- 5681-5685
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1996780383
- Cited by
- 126
- References
- 12
- FWCI
- 13.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucocorticoid-Induced Osteoporosis: Summary of a Workshop. https://app.cochat.ai/papers/10.1210/jcem.86.12.8066
- The paper
- Canalis, E., & Giustina, A. (2001). Glucocorticoid-Induced Osteoporosis: Summary of a Workshop. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jcem.86.12.8066
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.